Dr. Robin Vinck
Room 1F 153
+33 1 85 78 41 53
Robin was born in Marseilles, a large city in the south of France. In 2013 he obtained his technical degree in chemistry at Aix-Marseille University. He then studied at the Ecole Nationale Supérieure de Chimie de Montpellier where he specialized in pharmaceutical chemistry. He completed his Bachelor’s degree with a 2-month internship at the Institute of Cancer Therapeutics in Bradford (UK) where he worked on the synthesis of the CCR4 receptor inhibitors. In addition to his engineering degree in chemistry, he completed a Master’s degree in Biology in 2016 and worked for 6 month at the Institut Pasteur in Paris on the recombinant expression and purification of an azide-modified VHH antibody in order to develop a neuroregenerative peptide. Robin then undertook a PhD research project at CEA Saclay, in the south of Paris, under the supervision of Pr. Daniel Gillet and Dr. Jean-Christophe Cintrat and worked on the pharmaceutical development and in vivo study of a broad-spectrum anti-intracellular pathogens drug candidate. On this occasion, he had the opportunity to obtain his certification to perform in vivo studies.
Robin now works in the Gasser group on the in vivo application of new photosentisizers in order to validate a proof of concept of the use of Photodynamic therapy to fight cancer.
In his spare time, Robin enjoys analog photography, movies and whisky tasting.
 Pialat, A.; Bergès, J.; Sabourin, A.; Vinck, R.; Liégault, B.; Taillefer, M. Iodine(III)-Mediated Para-Selective Direct Imidation of Anilides. Chem. Eur. J., 2015, 21(28), 10014–10018.
 Couhert, A.; Vinck R.; Pruvost, A.; Barbier, J.; Gillet, D.; Cintrat, J.C. Nouvelles dihydroquinazolinones ayant une activité protectrice vis-à-vis de toxines au mode d’action intracellulaire, de virus et de bactéries. French Patent No. F0263S00662/FR/BN, 2018.
2011, 46, 150-159.